Advertisement

Journal of Gastroenterology

, Volume 44, Supplement 19, pp 96–101 | Cite as

The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology

  • Stephen Caldwell
  • Sang H. Park
International Forum 2

Abstract

The epidemiology of hepatocellular cancer (HCC) can be viewed from several important perspectives. The conventional perspective includes the overall public health impact of HCC, which is increasing in incidence in many regions of the world. The epidemiology of HCC can also be viewed from the perspective of variation in underlying disease associations such as viral hepatitis or the recently recognized link to nonalcoholic fatty liver disease (NAFLD). Of perhaps increasing importance with recent advances in therapy of HCC, the epidemiology of HCC can also be viewed from the perspective of variation in HCC biology. This lesser known perspective may depend in part on the underlying liver disease and the cell origin of the cancer, whether of hepatocyte or stem cell origin. This aspect is likely to become central to diagnosis and management of HCC with the further development of targeted therapeutics. The relative efficacy of these agents will likely depend on the biochemical pathways active in a given hepatocellular malignancy. This, in turn, is likely to be related to the epidemiological associations of HCC.

Key words

hepatocellular cancer viral hepatitis NASH NAFLD cirrhosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97(1):72–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153–156.PubMedCrossRefGoogle Scholar
  3. 3.
    Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5–S16.PubMedCrossRefGoogle Scholar
  4. 4.
    Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease 2005;9:191–211.PubMedCrossRefGoogle Scholar
  5. 5.
    Yu MW, Chang HC, Chang SC, Liaw YF, Lin SM, Liu CJ, et al. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology 2003;38:1393–1400.PubMedGoogle Scholar
  6. 6.
    De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol 2002;193:59–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Rogers AB, Theve EJ, Feng Y, Fry RC, Taghizadeh K, Clapp KM, et al. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res 2007;67:11536–11546.PubMedCrossRefGoogle Scholar
  8. 8.
    Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127(5 suppl 1):S17–S26.PubMedCrossRefGoogle Scholar
  9. 9.
    Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007;121(7):1624–1626.PubMedCrossRefGoogle Scholar
  10. 10.
    El-Serag HB, Mason HC. Rising incidence of hepatocellular carcinoma in the Unites States. N Engl J Med 1999;19:221–229.Google Scholar
  11. 11.
    Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ. Mortality and hospital utilization for hepatocellular cancer in the United States. Gastroenterology 2005;129:486–493.PubMedGoogle Scholar
  12. 12.
    El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Archives of Internal Medicine 2007;167:1983–1989.PubMedCrossRefGoogle Scholar
  13. 13.
    Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al. Liver Cancer Network. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98(9):2060–2063.PubMedCrossRefGoogle Scholar
  14. 14.
    Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127(5 suppl 1):S72–S78.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang Y-J, Chen Y, Ahsan H, Lunn RM, Chen S-Y, Lee PH, et al. Silencing glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular cancer. Cancer Lett 2005;221:135–143.PubMedCrossRefGoogle Scholar
  16. 16.
    Hoque A, Patt YZ, Yoffe B, Groopman JD, Greenblatt MS, Zhang YJ, et al. Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States? Nutr Cancer 1999;35:27–33.PubMedCrossRefGoogle Scholar
  17. 17.
    La Vecchia C. Alcohol and liver cancer. Eur J Cancer Prev 2007;16:495–497.PubMedGoogle Scholar
  18. 18.
    Hara M, Tanaka K, Higaki Y, Mizuta T, Eguchi Y, Yasutake T, et al. Case-control study on cigarette smoking and the risk of hepatocellular carcinoma among Japanese. Cancer Sci 2008;99:93–97.PubMedGoogle Scholar
  19. 19.
    Chiu HF, Ho SC, Wang LY, Wu TN, Yang CY. Does arsenic exposure increase the risk for liver cancer? J Toxicol Environ Health Part A 2004;67:1491–1500.PubMedCrossRefGoogle Scholar
  20. 20.
    Cotrim HP, Carvalho F, Siquiera AC, Lordelo M, Rocha R, De Freitas LA. Nonalcoholic fatty liver and insulin resistance among petrochemical workers. JAMA 2005;294:1618–1620.PubMedCrossRefGoogle Scholar
  21. 21.
    Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol 2007;22:1104–1111.PubMedCrossRefGoogle Scholar
  22. 22.
    Yu M-W, Yeh S-H, Chen P-J, Liaw Y-F, Lin C-L, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265–272.PubMedCrossRefGoogle Scholar
  23. 23.
    Changchien C-S, Chen C-L, Yen Y-H, Wang J-H, Hu T-H, Lee C-M, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcomes and survival. J Gastroenterol 2008;43:159–170.PubMedCrossRefGoogle Scholar
  24. 24.
    Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschenfelde K, Papakonstontinou A, et al. Impact of HBV, HCV, and GBV-C/HGV on hepatocellular carcinoma in Europe: results of a European concerted action. J Hepatol 1998;29:173–183.PubMedCrossRefGoogle Scholar
  25. 25.
    Park J-W. Hepatocellular carcinoma in Korea: introduction and overview. Korean J Gastroenterol 2005;45:217–226.PubMedGoogle Scholar
  26. 26.
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112(2):463–472.PubMedCrossRefGoogle Scholar
  27. 27.
    Seeff LB. The burden of hepatocellular carcinoma. Gastroenterology 2004;127:S1–S4.PubMedCrossRefGoogle Scholar
  28. 28.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–1917.PubMedCrossRefGoogle Scholar
  29. 29.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: AASLD Practice Guideline. Hepatology 2005;42:1208–1236.PubMedCrossRefGoogle Scholar
  30. 30.
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35–S50.PubMedCrossRefGoogle Scholar
  31. 31.
    Terasaki S, Kaneko S, Kobayashi K, Nonomura A, Nakanuma Y. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology 1998;115:1216–1222.PubMedCrossRefGoogle Scholar
  32. 32.
    Watanabe S, Horie Y, Kataoka E, Sato W, Dohmen T, Ohshima S, et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (Pten)-deficient mice. J Gastroenterol Hepatol 2007;22(suppl 1):S96–S100.PubMedCrossRefGoogle Scholar
  33. 33.
    Lew EA, Garfinkle L. Variation in mortality by weight among 750 000 men and women. J Chronic Dis 1979;32:563–76.PubMedCrossRefGoogle Scholar
  34. 34.
    Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Moller H, Mellemgaard A, Lindvig K, Olsen J. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:344–350.PubMedCrossRefGoogle Scholar
  36. 36.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625–1638.PubMedCrossRefGoogle Scholar
  37. 37.
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202–1219.PubMedCrossRefGoogle Scholar
  38. 38.
    El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001;96:2462–2467.PubMedCrossRefGoogle Scholar
  39. 39.
    Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami H-O. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Nat Cancer Inst 2000;92:1096–1099.PubMedCrossRefGoogle Scholar
  40. 40.
    Yu L, Sloan DA, Guo C, Howell CD. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol 2006;4:355–360.PubMedCrossRefGoogle Scholar
  41. 41.
    Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127(suppl 1):S97–S103.PubMedCrossRefGoogle Scholar
  42. 42.
    Caldwell SH, Crespo DM. Milestones in liver diseases. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2005;40:578–584.CrossRefGoogle Scholar
  43. 43.
    Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11:191–207.PubMedCrossRefGoogle Scholar
  44. 44.
    Ishii H. Hepatocellular carcinoma and non-alcoholic fatty liver disease: major liver diseases emerging from the Asia-Pacific Region. J Gastroenterol Hepatol 2006;21:6–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Park SH. Nonalcoholic steatohepatitis: pathogenesis and treatment. Korean J Hepatol 2008;14:12–27.PubMedCrossRefGoogle Scholar
  46. 46.
    Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007;11:191–207.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee V, Kleiner DE, Al-Osaimi AMS, Argo CK, Northup PG, Berg CL, et al. Histological characteristics of patients with “cryptogenic” cirrhosis and prior biopsy showing NASH. Hepatology 2007;46(suppl):743A.Google Scholar
  48. 48.
    Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349–1354.PubMedGoogle Scholar
  49. 49.
    Oh KC, Park SH, Park JC, Jin DK, Park CS, Kim KO, et al. Is the incidence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J Gastroenterol 2005;45:45–51.PubMedGoogle Scholar
  50. 50.
    Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other diseases. Hepatology 2005;42(1):5–12.PubMedCrossRefGoogle Scholar
  51. 51.
    Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer (Phila) 2003;97:3036–3043.CrossRefGoogle Scholar
  52. 52.
    Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (Phila) 2007;109:2490–2496.CrossRefGoogle Scholar
  53. 53.
    Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:459.PubMedCrossRefGoogle Scholar
  54. 54.
    Takuma Y, Nouso K, Makino Y, Saito S, Takayama H, Takahara M, et al. Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. Liver Int 2007;27(5):620–626.PubMedCrossRefGoogle Scholar
  55. 55.
    Pitot HC. Pathways of progression in hepatocarcinogenesis. Lancet 2001;358:859–860.PubMedCrossRefGoogle Scholar
  56. 56.
    Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163:1301–1311.PubMedGoogle Scholar
  57. 57.
    Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, et al. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis (Oxf) 2002;23:1781–1789.CrossRefGoogle Scholar
  58. 58.
    Rossmanith W, Schulte-Hermann R. Biology of transforming growth factor beta in hepatocarcinogenesis. Microsc Res Tech 2001;52:430–436.PubMedCrossRefGoogle Scholar
  59. 59.
    Sanchez A, Factor VM, Schroeder IS, Nagy P, Thorgeirsson SS. Activation of NF-κB and STAT3 in rat oval cells during 2-acetylaminoflourene/partial hepatectomy-induced liver regeneration. Hepatology 2004;39:376–385.PubMedCrossRefGoogle Scholar
  60. 60.
    Sasaki Y. Does oxidative stress participate in the development of hepatocellular cancer? J Gastroenterol 2006;41:1135–1148.PubMedCrossRefGoogle Scholar
  61. 61.
    Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology (Oxf) 2006;49:138–151.CrossRefGoogle Scholar
  62. 62.
    Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, et al. Progressive fibrosis in non-alcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007;133:80–90.PubMedCrossRefGoogle Scholar
  63. 63.
    Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005:41:809–818.PubMedCrossRefGoogle Scholar
  64. 64.
    Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 2008;47:511–520.PubMedCrossRefGoogle Scholar
  65. 65.
    Hytiroglou P, Park YN, Krinsky G, Theise ND. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin N Am 2007;36:867–887.CrossRefGoogle Scholar
  66. 66.
    Roskams T. Liver stem cells and their implications in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818–3822.PubMedCrossRefGoogle Scholar
  67. 67.
    Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851–857.PubMedCrossRefGoogle Scholar
  68. 68.
    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. A novel molecular classification of HCV-related hepatocellular carcinoma (HCC) based on integrative genomic analysis. J Hepatol 2008;48(S2):S12, EASL 2008.CrossRefGoogle Scholar
  69. 69.
    Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299:53–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2009

Authors and Affiliations

  • Stephen Caldwell
    • 1
  • Sang H. Park
    • 2
  1. 1.Division of Gastroenterology and Hepatology, Digestive Health Center of ExcellenceUniversity of Virginia Health SystemCharlottesvilleUSA
  2. 2.Hallym University Medical CenterSeoulKorea

Personalised recommendations